TGTX Profile — TG Therapeutics Inc
TG Therapeutics is a commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, Co. has received approval from the U.S. Food and Drug Administration for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Co. also evaluates products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
|
|
Free TGTX Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Buy (3.37 out of 4) 54th percentile
(ranked higher than approx. 54% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |